Skip To Main Content
Cheese Consumers on Muck Rack

Cheese Consumers

As seen in: MarketScreener, Mondaq
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cheese

Contact Cheese, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Welcome: Judith Hasko (Video)

|
By Cheese Consumers, Judith Hasko
| Mondaq
W WilmerHale More WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia. Meet Judith Hasko who joined WilmerHale in 2024 as a partner in our Palo Alto office and co-chair of the firm's Life Sciences practice.
Open in Who Shared View Duplicates (2) Issue with article?

Now Available! Updated Goodwin's Guide To Biosimilars Litigation And Regulation In The U.S., 2024-2025

|
By Cheese Consumers, Sarah Clarke
| Mondaq
As regular Big Molecule Watch readers know, the Biologics Price Competition and Innovation Act ("BPCIA") was signed into law as part of the Affordable Care Act on March 23, 2010, creating an abbreviated licensure pathway for "biosimilar" and "interchangeable" biological products.
Open in Who Shared Issue with article?

Post-Election Outlook: Issues To Watch For Pharmacy Industry Stakeholders

|
By Cheese Consumers, Steven Schnelle
| Mondaq
The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This On the Subject considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as Republican public policy momentum builds.
Open in Who Shared Issue with article?
See all 11 articles